Pages that link to "Q42662957"
Jump to navigation
Jump to search
The following pages link to Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. (Q42662957):
Displaying 50 items.
- Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease (Q26745663) (← links)
- Exacerbations of COPD (Q26764891) (← links)
- A rational approach to single, dual and triple therapy in COPD (Q26776477) (← links)
- Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review (Q28070274) (← links)
- Asthma-COPD Overlap Syndrome: What We Know and What We Don't (Q30238799) (← links)
- Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi (Q33576458) (← links)
- Blood and sputum eosinophils in COPD; relationship with bacterial load. (Q33651114) (← links)
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (Q34550471) (← links)
- Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses (Q36084073) (← links)
- Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial (Q36302882) (← links)
- Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice (Q36332206) (← links)
- Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. (Q37074953) (← links)
- Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts (Q37283465) (← links)
- Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on As (Q37374602) (← links)
- Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on As (Q37481285) (← links)
- Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention (Q37583834) (← links)
- Drugs for chronic obstructive pulmonary disease (Q37647174) (← links)
- Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD (Q38621360) (← links)
- When is dual bronchodilation indicated in COPD? (Q38641441) (← links)
- Fluticasone propionate/formoterol for COPD management: a randomized controlled trial (Q38663441) (← links)
- Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. (Q38685218) (← links)
- Reply to Correspondence Letter Regarding "Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial". (Q38708919) (← links)
- Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease. (Q38710985) (← links)
- Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink (Q38751378) (← links)
- Prediction and prevention of exacerbations and mortality in patients with COPD. (Q38823010) (← links)
- Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial (Q38849442) (← links)
- Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease (Q38901257) (← links)
- Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study (Q38934768) (← links)
- How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? (Q39030602) (← links)
- Eosinophilic and Neutrophilic Airway Inflammation in the Phenotyping of Mild-to-Moderate Asthma and Chronic Obstructive Pulmonary Disease (Q39094807) (← links)
- Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence (Q39173650) (← links)
- Eosinophils in COPD: just another biomarker? (Q39364408) (← links)
- Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. (Q39367877) (← links)
- Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis (Q39558323) (← links)
- Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. (Q40598255) (← links)
- Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease (Q41658426) (← links)
- Systemic White Blood Cell Count as a Biomarker for Chronic Obstructive Pulmonary Disease: Utility and Limitations (Q42337197) (← links)
- Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma (Q42358548) (← links)
- Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017. (Q42701518) (← links)
- Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (Q42920605) (← links)
- Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort (Q46434748) (← links)
- A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. (Q47138049) (← links)
- Recommendations for the pharmacological treatment of COPD: questions and answers. (Q47272746) (← links)
- Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials (Q47645481) (← links)
- Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. (Q47661714) (← links)
- ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils. (Q47677775) (← links)
- Eosinophils in COPD: are we nearly there yet? (Q47709236) (← links)
- Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine (Q47718704) (← links)
- Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study. (Q47724396) (← links)
- A pragmatic approach to simplify inhaler therapy for COPD. (Q47838017) (← links)